<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02355665</url>
  </required_header>
  <id_info>
    <org_study_id>CO-140121222102-SCCT</org_study_id>
    <nct_id>NCT02355665</nct_id>
  </id_info>
  <brief_title>Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Using a Naturalistic Clinical Model to Measure the Efficacy and Safety of a Novel Nicotine Replacement Therapy in Smokers Motivated to Quit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>McNeil AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of a novel nicotine product
      for continuous abstinence from smoking. Efficacy of product will be evaluated by assessments
      of self-reported abstinence, verified by exhaled carbon monoxide (CO) levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2015</start_date>
  <completion_date type="Actual">February 10, 2016</completion_date>
  <primary_completion_date type="Actual">September 30, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 6</measure>
    <time_frame>Week 2 to Week 6</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 12</measure>
    <time_frame>Week 2 to Week 12</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 26</measure>
    <time_frame>Week 2 to Week 26</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 4</measure>
    <time_frame>Week 2 to Week 4</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 8</measure>
    <time_frame>Week 2 to Week 8</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 16</measure>
    <time_frame>Week 2 to Week 16</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 20</measure>
    <time_frame>Week 2 to Week 20</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggregated Withdrawal Score at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggregated Withdrawal Score at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggregated Withdrawal Score at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggregated Withdrawal Score at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 3</measure>
    <time_frame>Week 3</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 5</measure>
    <time_frame>Week 5</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 7</measure>
    <time_frame>Week 7</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 9</measure>
    <time_frame>Week 9</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 11</measure>
    <time_frame>Week 11</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 13</measure>
    <time_frame>Week 13</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 14</measure>
    <time_frame>Week 14</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 15</measure>
    <time_frame>Week 15</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 17</measure>
    <time_frame>Week 17</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 18</measure>
    <time_frame>Week 18</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 19</measure>
    <time_frame>Week 19</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 20</measure>
    <time_frame>Week 20</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 21</measure>
    <time_frame>Week 21</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 22</measure>
    <time_frame>Week 22</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 23</measure>
    <time_frame>Week 23</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 25</measure>
    <time_frame>Week 25</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Number of Self-Reported Spray Doses at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 3</measure>
    <time_frame>Week 3</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 5</measure>
    <time_frame>Week 5</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 7</measure>
    <time_frame>Week 7</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 9</measure>
    <time_frame>Week 9</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 11</measure>
    <time_frame>Week 11</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 13</measure>
    <time_frame>Week 13</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 14</measure>
    <time_frame>Week 14</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 15</measure>
    <time_frame>Week 15</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 17</measure>
    <time_frame>Week 17</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 18</measure>
    <time_frame>Week 18</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 19</measure>
    <time_frame>Week 19</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 20</measure>
    <time_frame>Week 20</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 21</measure>
    <time_frame>Week 21</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 22</measure>
    <time_frame>Week 22</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 23</measure>
    <time_frame>Week 23</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 25</measure>
    <time_frame>Week 25</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Total Daily Number of Self-Reported Spray Doses at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 3</measure>
    <time_frame>Week 3</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 5</measure>
    <time_frame>Week 5</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 7</measure>
    <time_frame>Week 7</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 9</measure>
    <time_frame>Week 9</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 11</measure>
    <time_frame>Week 11</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 13</measure>
    <time_frame>Week 13</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 14</measure>
    <time_frame>Week 14</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 15</measure>
    <time_frame>Week 15</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 17</measure>
    <time_frame>Week 17</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 18</measure>
    <time_frame>Week 18</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 19</measure>
    <time_frame>Week 19</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 20</measure>
    <time_frame>Week 20</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 21</measure>
    <time_frame>Week 21</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 22</measure>
    <time_frame>Week 22</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 23</measure>
    <time_frame>Week 23</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 25</measure>
    <time_frame>Week 25</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Hourly Number of Self-Reported Spray Doses at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cigarettes Smoked Since Last Visit at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Number of Cigarettes Smoked Since Last Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cigarettes Smoked Since Last Visit at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Number of Cigarettes Smoked Since Last Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cigarettes Smoked Per Day at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Number of Cigarettes Smoked Per Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cigarettes Smoked Per Day at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Number of Cigarettes Smoked Per Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cigarettes Smoked Per Day at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Number of Cigarettes Smoked Per Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cigarettes Smoked Per Day at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Number of Cigarettes Smoked Per Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cigarettes Smoked Per Day at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Number of Cigarettes Smoked Per Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cigarettes Smoked Per Day at Week 20</measure>
    <time_frame>Week 20</time_frame>
    <description>Number of Cigarettes Smoked Per Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cigarettes Smoked Per Day at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Number of Cigarettes Smoked Per Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Overall Product Rating at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Overall Product Rating at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Overall Product Rating at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Speed of Action of the Product at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Speed of Action of the Product at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Speed of Action of the Product at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Change of Opinion at Week 1 Concerning Product Compared to When First Used Product</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Change of Opinion at Week 6 Concerning Product Compared to When First Used Product</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Change of Opinion at Week 12 Concerning Product Compared to When First Used Product</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Product Convenience at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Product Convenience at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Product Convenience at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure at Week 20</measure>
    <time_frame>Week 20</time_frame>
    <description>Systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Week 1</measure>
    <time_frame>Baseline to Week 1</time_frame>
    <description>Change from baseline in systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Week 2</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>Change from baseline in systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change from baseline in systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Week 6</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>Change from baseline in systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Change from baseline in systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Change from baseline in systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Week 20</measure>
    <time_frame>Baseline to Week 20</time_frame>
    <description>Change from baseline in systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Week 26</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Change from baseline in systolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure at Week 20</measure>
    <time_frame>Week 20</time_frame>
    <description>Diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Week 1</measure>
    <time_frame>Baseline to Week 1</time_frame>
    <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Week 2</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Week 6</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Week 20</measure>
    <time_frame>Baseline to Week 20</time_frame>
    <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Week 26</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse at Week 1</measure>
    <time_frame>Week 1</time_frame>
    <description>Pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse at Week 20</measure>
    <time_frame>Week 20</time_frame>
    <description>Pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse at Week 1</measure>
    <time_frame>Baseline to Week 1</time_frame>
    <description>Change from baseline in pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse at Week 2</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>Change from baseline in pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change from baseline in pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse at Week 6</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>Change from baseline in pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Change from baseline in pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse at Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Change from baseline in pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse at Week 20</measure>
    <time_frame>Baseline to Week 20</time_frame>
    <description>Change from baseline in pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse at Week 26</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Change from baseline in pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New or Worsened Conditions in Lips/Labial Mucosa at Week 6 or When Withdrawn From Study</measure>
    <time_frame>Week 6 or when withdrawn from study</time_frame>
    <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New or Worsened Conditions in Buccal Mucosa at Week 6 or When Withdrawn From Study</measure>
    <time_frame>Week 6 or when withdrawn from study</time_frame>
    <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New or Worsened Conditions in Mucobuccal Fold at Week 6 or When Withdrawn From Study</measure>
    <time_frame>Week 6 or when withdrawn from study</time_frame>
    <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New or Worsened Conditions in Sublingual Mucosa at Week 6 or When Withdrawn From Study</measure>
    <time_frame>Week 6 or when withdrawn from study</time_frame>
    <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New or Worsened Conditions in Gingiva at Week 6 or When Withdrawn From Study</measure>
    <time_frame>Week 6 or when withdrawn from study</time_frame>
    <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New or Worsened Conditions in Tongue at Week 6 or When Withdrawn From Study</measure>
    <time_frame>Week 6 or when withdrawn from study</time_frame>
    <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New or Worsened Conditions in Hard/Soft Palate at Week 6 or When Withdrawn From Study</measure>
    <time_frame>Week 6 or when withdrawn from study</time_frame>
    <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New or Worsened Conditions in Uvula/Oropharynx at Week 6 or When Withdrawn From Study</measure>
    <time_frame>Week 6 or when withdrawn from study</time_frame>
    <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New or Worsened Conditions in Visual Mouth Inspection Overall at Week 6 or When Withdrawn From Study</measure>
    <time_frame>Week 6 or when withdrawn from study</time_frame>
    <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 6</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>Change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 26</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 6 in Participants Verified Continuously Abstinent From Smoking From the Week 2 Visit</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>Change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 12 in Participants Verified Continuously Abstinent From Smoking From the Week 2 Visit</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 26 in Participants Verified Continuously Abstinent From Smoking From the Week 2 Visit</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Change from baseline in body weight</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1198</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>Nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotine Spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match Nicotine spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Spray</intervention_name>
    <description>Nicotine Spray</description>
    <arm_group_label>Nicotine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match nicotine spray</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must be males or females 18-85 years of age who currently smoke cigarettes daily
        and are willing to stop smoking

        Exclusion Criteria:

        History of cardiovascular disease, stomach ulcer or diabetes unless physician's written
        approval is obtained.

        Use of other forms of tobacco/nicotine containing products other than cigarettes within 30
        days before baseline visit.

        Use of nicotine replacement therapies or other smoking cessation medicines/non-drug
        therapies within 30 days before the baseline visit.

        Pregnancy or intending to become pregnant.

        Hypersensitivity to the product, history of alcohol or substance abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Myers, MD</last_name>
    <role>Study Director</role>
    <affiliation>McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles Clinical Trials</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>College Park</city>
        <state>Maryland</state>
        <zip>20742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2015</study_first_posted>
  <results_first_submitted>November 13, 2018</results_first_submitted>
  <results_first_submitted_qc>December 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2019</results_first_posted>
  <disposition_first_submitted>July 26, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>August 26, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 30, 2016</disposition_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
        </group>
        <group group_id="P2">
          <title>Nicotine</title>
          <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="601"/>
                <participants group_id="P2" count="597"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="352"/>
                <participants group_id="P2" count="365"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Compliance, PI decision, move, eligible</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was based on the Full Analysis Set which included all study participants randomly assigned to study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
        </group>
        <group group_id="B2">
          <title>Nicotine</title>
          <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="601"/>
            <count group_id="B2" value="597"/>
            <count group_id="B3" value="1198"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="11.72"/>
                    <measurement group_id="B2" value="51.5" spread="11.7"/>
                    <measurement group_id="B3" value="51.3" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="319"/>
                    <measurement group_id="B2" value="332"/>
                    <measurement group_id="B3" value="651"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <title>USA</title>
                  <measurement_list>
                    <measurement group_id="B1" value="601"/>
                    <measurement group_id="B2" value="597"/>
                    <measurement group_id="B3" value="1198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 6</title>
        <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
        <time_frame>Week 2 to Week 6</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 6</title>
          <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in continuous smoking abstinence rates between treatments. The alternative hypothesis was a difference in continuous smoking abstinence rates between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by study site and number of cigarettes smoked per day at baseline (&lt;20 per day vs 20 per day).</method_desc>
            <param_type>Estimated Success Rate Ratio</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>3.66</ci_upper_limit>
            <estimate_desc>Estimated Success Rate Ratio = Nicotine/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 12</title>
        <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
        <time_frame>Week 2 to Week 12</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 12</title>
          <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in continuous smoking abstinence rates between treatments. The alternative hypothesis was a difference in continuous smoking abstinence rates between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by study site and number of cigarettes smoked per day at baseline (&lt;20 per day vs 20 per day).</method_desc>
            <param_type>Estimated Success Rate Ratio</param_type>
            <param_value>3.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.39</ci_lower_limit>
            <ci_upper_limit>6.68</ci_upper_limit>
            <estimate_desc>Estimated Success Rate Ratio = Nicotine/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 26</title>
        <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
        <time_frame>Week 2 to Week 26</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 26</title>
          <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in continuous smoking abstinence rates between treatments. The alternative hypothesis was a difference in continuous smoking abstinence rates between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by study site and number of cigarettes smoked per day at baseline (&lt;20 per day vs 20 per day).</method_desc>
            <param_type>Estimated Success Rate Ratio</param_type>
            <param_value>2.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>6.71</ci_upper_limit>
            <estimate_desc>Estimated Success Rate Ratio = Nicotine/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 4</title>
        <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
        <time_frame>Week 2 to Week 4</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 4</title>
          <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in continuous smoking abstinence rates between treatments. The alternative hypothesis was a difference in continuous smoking abstinence rates between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.040</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by study site and number of cigarettes smoked per day at baseline (&lt;20 per day vs 20 per day).</method_desc>
            <param_type>Estimated Success Rate Ratio</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>2.71</ci_upper_limit>
            <estimate_desc>Estimated Success Rate Ratio = Nicotine/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 8</title>
        <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
        <time_frame>Week 2 to Week 8</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 8</title>
          <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in continuous smoking abstinence rates between treatments. The alternative hypothesis was a difference in continuous smoking abstinence rates between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by study site and number of cigarettes smoked per day at baseline (&lt;20 per day vs 20 per day).</method_desc>
            <param_type>Estimated Success Rate Ratio</param_type>
            <param_value>2.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>3.98</ci_upper_limit>
            <estimate_desc>Estimated Success Rate Ratio = Nicotine/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 16</title>
        <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
        <time_frame>Week 2 to Week 16</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 16</title>
          <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in continuous smoking abstinence rates between treatments. The alternative hypothesis was a difference in continuous smoking abstinence rates between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by study site and number of cigarettes smoked per day at baseline (&lt;20 per day vs 20 per day).</method_desc>
            <param_type>Estimated Success Rate Ratio</param_type>
            <param_value>2.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.32</ci_lower_limit>
            <ci_upper_limit>6.42</ci_upper_limit>
            <estimate_desc>Estimated Success Rate Ratio = Nicotine/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 20</title>
        <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
        <time_frame>Week 2 to Week 20</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 20</title>
          <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in continuous smoking abstinence rates between treatments. The alternative hypothesis was a difference in continuous smoking abstinence rates between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by study site and number of cigarettes smoked per day at baseline (&lt;20 per day vs 20 per day).</method_desc>
            <param_type>Estimated Success Rate Ratio</param_type>
            <param_value>2.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>5.92</ci_upper_limit>
            <estimate_desc>Estimated Success Rate Ratio = Nicotine/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 1</title>
        <description>Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 1</title>
          <description>Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of desire/urge to smoke between treatments. The alternative hypothesis was a difference in distribution of the ratings of desire/urge to smoke between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.847</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 2</title>
        <description>Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 2</title>
          <description>Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0"/>
                    <measurement group_id="O2" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0"/>
                    <measurement group_id="O2" value="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of desire/urge to smoke between treatments. The alternative hypothesis was a difference in distribution of the ratings of desire/urge to smoke between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.861</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 4</title>
        <description>Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 4</title>
          <description>Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                    <measurement group_id="O2" value="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8"/>
                    <measurement group_id="O2" value="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of desire/urge to smoke between treatments. The alternative hypothesis was a difference in distribution of the ratings of desire/urge to smoke between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.266</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 6</title>
        <description>Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 6</title>
          <description>Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                    <measurement group_id="O2" value="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3"/>
                    <measurement group_id="O2" value="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of desire/urge to smoke between treatments. The alternative hypothesis was a difference in distribution of the ratings of desire/urge to smoke between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.487</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 1</title>
        <description>Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 1</title>
          <description>Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of irritability/frustration/anger between treatments. The alternative hypothesis was a difference in distribution of the ratings of irritability/frustration/anger between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.433</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 2</title>
        <description>Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 2</title>
          <description>Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0"/>
                    <measurement group_id="O2" value="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of irritability/frustration/anger between treatments. The alternative hypothesis was a difference in distribution of the ratings of irritability/frustration/anger between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.15</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 4</title>
        <description>Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 4</title>
          <description>Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                    <measurement group_id="O2" value="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of irritability/frustration/anger between treatments. The alternative hypothesis was a difference in distribution of the ratings of irritability/frustration/anger between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.665</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 6</title>
        <description>Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 6</title>
          <description>Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                    <measurement group_id="O2" value="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                    <measurement group_id="O2" value="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of irritability/frustration/anger between treatments. The alternative hypothesis was a difference in distribution of the ratings of irritability/frustration/anger between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.300</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 1</title>
        <description>Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 1</title>
          <description>Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6"/>
                    <measurement group_id="O2" value="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of restlessness between treatments. The alternative hypothesis was a difference in distribution of the ratings of restlessness between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.754</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 2</title>
        <description>Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 2</title>
          <description>Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0"/>
                    <measurement group_id="O2" value="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of restlessness between treatments. The alternative hypothesis was a difference in distribution of the ratings of restlessness between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.116</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 4</title>
        <description>Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 4</title>
          <description>Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8"/>
                    <measurement group_id="O2" value="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                    <measurement group_id="O2" value="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of restlessness between treatments. The alternative hypothesis was a difference in distribution of the ratings of restlessness between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.392</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 6</title>
        <description>Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 6</title>
          <description>Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                    <measurement group_id="O2" value="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of restlessness between treatments. The alternative hypothesis was a difference in distribution of the ratings of restlessness between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.179</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 1</title>
        <description>Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 1</title>
          <description>Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of difficulty concentrating between treatments. The alternative hypothesis was a difference in distribution of the ratings of difficulty concentrating between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.925</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 2</title>
        <description>Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 2</title>
          <description>Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0"/>
                    <measurement group_id="O2" value="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0"/>
                    <measurement group_id="O2" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of difficulty concentrating between treatments. The alternative hypothesis was a difference in distribution of the ratings of difficulty concentrating between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.325</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 4</title>
        <description>Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 4</title>
          <description>Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1"/>
                    <measurement group_id="O2" value="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of difficulty concentrating between treatments. The alternative hypothesis was a difference in distribution of the ratings of difficulty concentrating between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.891</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 6</title>
        <description>Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 6</title>
          <description>Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9"/>
                    <measurement group_id="O2" value="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of difficulty concentrating between treatments. The alternative hypothesis was a difference in distribution of the ratings of difficulty concentrating between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.721</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 1</title>
        <description>Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 1</title>
          <description>Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4"/>
                    <measurement group_id="O2" value="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of anxiety between treatments. The alternative hypothesis was a difference in distribution of the ratings of anxiety between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.608</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 2</title>
        <description>Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 2</title>
          <description>Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0"/>
                    <measurement group_id="O2" value="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0"/>
                    <measurement group_id="O2" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of anxiety between treatments. The alternative hypothesis was a difference in distribution of the ratings of anxiety between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 4</title>
        <description>Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 4</title>
          <description>Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4"/>
                    <measurement group_id="O2" value="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9"/>
                    <measurement group_id="O2" value="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of anxiety between treatments. The alternative hypothesis was a difference in distribution of the ratings of anxiety between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.900</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 6</title>
        <description>Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 6</title>
          <description>Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of anxiety between treatments. The alternative hypothesis was a difference in distribution of the ratings of anxiety between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.731</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 1</title>
        <description>Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 1</title>
          <description>Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0"/>
                    <measurement group_id="O2" value="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of dysphoric or depressed mood between treatments. The alternative hypothesis was a difference in distribution of the ratings of dysphoric or depressed mood between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.635</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 2</title>
        <description>Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 2</title>
          <description>Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0"/>
                    <measurement group_id="O2" value="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of dysphoric or depressed mood between treatments. The alternative hypothesis was a difference in distribution of the ratings of dysphoric or depressed mood between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.273</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 4</title>
        <description>Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 4</title>
          <description>Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6"/>
                    <measurement group_id="O2" value="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of dysphoric or depressed mood between treatments. The alternative hypothesis was a difference in distribution of the ratings of dysphoric or depressed mood between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.879</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 6</title>
        <description>Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 6</title>
          <description>Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.1"/>
                    <measurement group_id="O2" value="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of dysphoric or depressed mood between treatments. The alternative hypothesis was a difference in distribution of the ratings of dysphoric or depressed mood between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.823</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 1</title>
        <description>Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 1</title>
          <description>Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2"/>
                    <measurement group_id="O2" value="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of insomnia between treatments. The alternative hypothesis was a difference in distribution of the ratings of insomnia between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.804</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 2</title>
        <description>Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 2</title>
          <description>Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of insomnia between treatments. The alternative hypothesis was a difference in distribution of the ratings of insomnia between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.438</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 4</title>
        <description>Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 4</title>
          <description>Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5"/>
                    <measurement group_id="O2" value="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9"/>
                    <measurement group_id="O2" value="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of insomnia between treatments. The alternative hypothesis was a difference in distribution of the ratings of insomnia between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.517</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 6</title>
        <description>Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 6</title>
          <description>Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of insomnia between treatments. The alternative hypothesis was a difference in distribution of the ratings of insomnia between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 1</title>
        <description>Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 1</title>
          <description>Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4"/>
                    <measurement group_id="O2" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of increased appetite between treatments. The alternative hypothesis was a difference in distribution of the ratings of increased appetite between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.105</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 2</title>
        <description>Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 2</title>
          <description>Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0"/>
                    <measurement group_id="O2" value="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0"/>
                    <measurement group_id="O2" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0"/>
                    <measurement group_id="O2" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of increased appetite between treatments. The alternative hypothesis was a difference in distribution of the ratings of increased appetite between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.604</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 4</title>
        <description>Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 4</title>
          <description>Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9"/>
                    <measurement group_id="O2" value="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of increased appetite between treatments. The alternative hypothesis was a difference in distribution of the ratings of increased appetite between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.194</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 6</title>
        <description>Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 6</title>
          <description>Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9"/>
                    <measurement group_id="O2" value="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                    <measurement group_id="O2" value="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of the ratings of increased appetite between treatments. The alternative hypothesis was a difference in distribution of the ratings of increased appetite between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.502</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aggregated Withdrawal Score at Week 1</title>
        <description>Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Aggregated Withdrawal Score at Week 1</title>
          <description>Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="4.25"/>
                    <measurement group_id="O2" value="4.5" spread="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of aggregated withdrawal scores between treatments. The alternative hypothesis was a difference in distribution of aggregated withdrawal scores between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.483</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.84</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aggregated Withdrawal Score at Week 2</title>
        <description>Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Aggregated Withdrawal Score at Week 2</title>
          <description>Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="5.46"/>
                    <measurement group_id="O2" value="4.5" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of aggregated withdrawal scores between treatments. The alternative hypothesis was a difference in distribution of aggregated withdrawal scores between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.102</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.24</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aggregated Withdrawal Score at Week 4</title>
        <description>Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Aggregated Withdrawal Score at Week 4</title>
          <description>Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="3.53"/>
                    <measurement group_id="O2" value="3.7" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of aggregated withdrawal scores between treatments. The alternative hypothesis was a difference in distribution of aggregated withdrawal scores between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.532</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.27</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aggregated Withdrawal Score at Week 6</title>
        <description>Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Aggregated Withdrawal Score at Week 6</title>
          <description>Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.</description>
          <population>Analysis was based on randomized participants verified abstinent from smoking since the last visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="5.11"/>
                    <measurement group_id="O2" value="3.8" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in distribution of aggregated withdrawal scores between treatments. The alternative hypothesis was a difference in distribution of aggregated withdrawal scores between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.354</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Estimated Mean Difference</param_type>
            <param_value>-1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.93</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
            <estimate_desc>Estimated Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 1</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 1</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="10.77"/>
                    <measurement group_id="O2" value="12.3" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 2</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 2</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="12.08"/>
                    <measurement group_id="O2" value="11.8" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 3</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 3</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 3</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="467"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="11.15"/>
                    <measurement group_id="O2" value="11.6" spread="9.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 4</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 4</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
                <count group_id="O2" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="11.05"/>
                    <measurement group_id="O2" value="11.3" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 5</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 5</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 5</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="12.17"/>
                    <measurement group_id="O2" value="10.9" spread="9.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 6</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 6</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="406"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="10.49"/>
                    <measurement group_id="O2" value="10.5" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 7</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 7</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 7</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="9.63"/>
                    <measurement group_id="O2" value="9.9" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 8</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 8</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 8</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="10.15"/>
                    <measurement group_id="O2" value="10.1" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 9</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 9</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 9</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="362"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="9.98"/>
                    <measurement group_id="O2" value="9.7" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 10</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 10</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 10</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="9.86"/>
                    <measurement group_id="O2" value="9.3" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 11</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 11</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 11</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="9.80"/>
                    <measurement group_id="O2" value="8.8" spread="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 12</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 12</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="7.69"/>
                    <measurement group_id="O2" value="7.9" spread="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 13</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 13</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 13</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="8.28"/>
                    <measurement group_id="O2" value="8.4" spread="8.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 14</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 14</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 14</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="9.20"/>
                    <measurement group_id="O2" value="9.2" spread="12.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 15</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 15</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 15</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="9.66"/>
                    <measurement group_id="O2" value="8.2" spread="8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 16</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 16</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 16</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="8.70"/>
                    <measurement group_id="O2" value="8.0" spread="8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 17</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 17</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 17</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="8.58"/>
                    <measurement group_id="O2" value="8.0" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 18</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 18</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 18</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="8.84"/>
                    <measurement group_id="O2" value="8.2" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 19</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 19</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 19</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="8.49"/>
                    <measurement group_id="O2" value="8.3" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 20</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 20</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 20</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="6.94"/>
                    <measurement group_id="O2" value="8.2" spread="8.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 21</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 21</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 21</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="7.32"/>
                    <measurement group_id="O2" value="8.2" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 22</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 22</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 22</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="7.27"/>
                    <measurement group_id="O2" value="7.8" spread="8.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 23</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 23</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 23</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="6.97"/>
                    <measurement group_id="O2" value="7.4" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 24</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 24</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 24</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="6.50"/>
                    <measurement group_id="O2" value="7.2" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 25</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 25</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 25</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="6.08"/>
                    <measurement group_id="O2" value="6.7" spread="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Number of Self-Reported Spray Doses at Week 26</title>
        <description>Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 26</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Number of Self-Reported Spray Doses at Week 26</title>
          <description>Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="5.91"/>
                    <measurement group_id="O2" value="6.3" spread="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 1</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 1</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="17.66"/>
                    <measurement group_id="O2" value="17.2" spread="11.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 2</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 2</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="16.83"/>
                    <measurement group_id="O2" value="15.4" spread="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 3</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 3</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 3</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="467"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="14.78"/>
                    <measurement group_id="O2" value="15.2" spread="13.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 4</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 4</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
                <count group_id="O2" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="13.58"/>
                    <measurement group_id="O2" value="15.8" spread="23.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 5</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 5</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 5</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="30.71"/>
                    <measurement group_id="O2" value="15.1" spread="27.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 6</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 6</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="406"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="14.59"/>
                    <measurement group_id="O2" value="14.6" spread="24.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 7</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 7</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 7</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="12.39"/>
                    <measurement group_id="O2" value="12.8" spread="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 8</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 8</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 8</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="13.05"/>
                    <measurement group_id="O2" value="13.6" spread="14.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 9</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 9</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 9</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="362"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="13.53"/>
                    <measurement group_id="O2" value="12.2" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 10</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 10</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 10</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="12.47"/>
                    <measurement group_id="O2" value="11.4" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 11</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 11</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 11</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="26.23"/>
                    <measurement group_id="O2" value="11.2" spread="11.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 12</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 12</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="9.70"/>
                    <measurement group_id="O2" value="9.8" spread="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 13</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 13</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 13</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="9.78"/>
                    <measurement group_id="O2" value="10.5" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 14</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 14</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 14</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="10.95"/>
                    <measurement group_id="O2" value="13.6" spread="40.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 15</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 15</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 15</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="30.31"/>
                    <measurement group_id="O2" value="10.8" spread="12.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 16</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 16</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 16</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="12.80"/>
                    <measurement group_id="O2" value="10.0" spread="9.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 17</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 17</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 17</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="10.19"/>
                    <measurement group_id="O2" value="10.5" spread="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 18</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 18</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 18</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="11.94"/>
                    <measurement group_id="O2" value="10.3" spread="10.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 19</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 19</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 19</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="9.85"/>
                    <measurement group_id="O2" value="10.3" spread="10.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 20</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 20</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 20</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="9.38"/>
                    <measurement group_id="O2" value="10.5" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 21</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 21</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 21</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="8.82"/>
                    <measurement group_id="O2" value="11.0" spread="13.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 22</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 22</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 22</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="8.89"/>
                    <measurement group_id="O2" value="10.8" spread="16.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 23</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 23</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 23</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="12.79"/>
                    <measurement group_id="O2" value="9.1" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 24</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 24</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 24</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="8.50"/>
                    <measurement group_id="O2" value="8.8" spread="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 25</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 25</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 25</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="7.24"/>
                    <measurement group_id="O2" value="8.4" spread="9.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 26</title>
        <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
        <time_frame>Week 26</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Total Daily Number of Self-Reported Spray Doses at Week 26</title>
          <description>Maximum Total Daily Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="7.30"/>
                    <measurement group_id="O2" value="7.9" spread="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 1</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 1</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="7.11"/>
                    <measurement group_id="O2" value="4.8" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 2</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 2</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="6.13"/>
                    <measurement group_id="O2" value="3.4" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 3</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 3</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 3</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="467"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="4.93"/>
                    <measurement group_id="O2" value="3.1" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 4</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 4</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
                <count group_id="O2" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="4.49"/>
                    <measurement group_id="O2" value="3.0" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 5</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 5</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 5</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="3.73"/>
                    <measurement group_id="O2" value="2.8" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 6</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 6</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="406"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="4.23"/>
                    <measurement group_id="O2" value="2.7" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 7</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 7</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 7</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="4.88"/>
                    <measurement group_id="O2" value="2.9" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 8</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 8</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 8</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="3.31"/>
                    <measurement group_id="O2" value="2.6" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 9</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 9</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 9</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="362"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="3.52"/>
                    <measurement group_id="O2" value="2.3" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 10</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 10</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 10</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="3.28"/>
                    <measurement group_id="O2" value="2.3" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 11</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 11</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 11</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="2.65"/>
                    <measurement group_id="O2" value="2.2" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 12</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 12</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.84"/>
                    <measurement group_id="O2" value="2.0" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 13</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 13</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 13</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="2.65"/>
                    <measurement group_id="O2" value="2.2" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 14</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 14</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 14</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.69"/>
                    <measurement group_id="O2" value="2.2" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 15</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 15</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 15</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="2.30"/>
                    <measurement group_id="O2" value="2.4" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 16</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 16</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 16</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="3.24"/>
                    <measurement group_id="O2" value="2.1" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 17</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 17</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 17</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.75"/>
                    <measurement group_id="O2" value="2.1" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 18</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 18</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 18</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.22"/>
                    <measurement group_id="O2" value="2.3" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 19</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 19</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 19</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="3.02"/>
                    <measurement group_id="O2" value="2.3" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 20</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 20</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 20</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.56"/>
                    <measurement group_id="O2" value="2.0" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 21</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 21</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 21</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.52"/>
                    <measurement group_id="O2" value="2.1" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 22</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 22</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 22</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.86"/>
                    <measurement group_id="O2" value="2.0" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 23</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 23</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 23</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.92"/>
                    <measurement group_id="O2" value="2.0" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 24</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 24</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 24</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="4.23"/>
                    <measurement group_id="O2" value="1.9" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 25</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 25</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 25</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.33"/>
                    <measurement group_id="O2" value="1.8" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 26</title>
        <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
        <time_frame>Week 26</time_frame>
        <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hourly Number of Self-Reported Spray Doses at Week 26</title>
          <description>Maximum Hourly Number of Self-Reported Spray Doses</description>
          <population>Analysis was based on randomized participants who reported use data for at least 4 of the days in that week.</population>
          <units>Number of sprays</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.59"/>
                    <measurement group_id="O2" value="1.8" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cigarettes Smoked Since Last Visit at Week 1</title>
        <description>Number of Cigarettes Smoked Since Last Visit</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on randomized participants who reported non-abstinence from smoking since last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cigarettes Smoked Since Last Visit at Week 1</title>
          <description>Number of Cigarettes Smoked Since Last Visit</description>
          <population>Analysis was based on randomized participants who reported non-abstinence from smoking since last visit.</population>
          <units>Number of cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="37.89"/>
                    <measurement group_id="O2" value="34.0" spread="40.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cigarettes Smoked Since Last Visit at Week 2</title>
        <description>Number of Cigarettes Smoked Since Last Visit</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on randomized participants who reported non-abstinence from smoking since last visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cigarettes Smoked Since Last Visit at Week 2</title>
          <description>Number of Cigarettes Smoked Since Last Visit</description>
          <population>Analysis was based on randomized participants who reported non-abstinence from smoking since last visit.</population>
          <units>Number of cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="472"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="44.21"/>
                    <measurement group_id="O2" value="35.8" spread="48.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cigarettes Smoked Per Day at Week 4</title>
        <description>Number of Cigarettes Smoked Per Day</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cigarettes Smoked Per Day at Week 4</title>
          <description>Number of Cigarettes Smoked Per Day</description>
          <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
          <units>Number of cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="7.77"/>
                    <measurement group_id="O2" value="6.6" spread="8.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cigarettes Smoked Per Day at Week 6</title>
        <description>Number of Cigarettes Smoked Per Day</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cigarettes Smoked Per Day at Week 6</title>
          <description>Number of Cigarettes Smoked Per Day</description>
          <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
          <units>Number of cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="412"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="7.63"/>
                    <measurement group_id="O2" value="6.6" spread="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cigarettes Smoked Per Day at Week 8</title>
        <description>Number of Cigarettes Smoked Per Day</description>
        <time_frame>Week 8</time_frame>
        <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cigarettes Smoked Per Day at Week 8</title>
          <description>Number of Cigarettes Smoked Per Day</description>
          <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
          <units>Number of cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="5.82"/>
                    <measurement group_id="O2" value="6.3" spread="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cigarettes Smoked Per Day at Week 12</title>
        <description>Number of Cigarettes Smoked Per Day</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cigarettes Smoked Per Day at Week 12</title>
          <description>Number of Cigarettes Smoked Per Day</description>
          <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
          <units>Number of cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="5.94"/>
                    <measurement group_id="O2" value="7.5" spread="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cigarettes Smoked Per Day at Week 16</title>
        <description>Number of Cigarettes Smoked Per Day</description>
        <time_frame>Week 16</time_frame>
        <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cigarettes Smoked Per Day at Week 16</title>
          <description>Number of Cigarettes Smoked Per Day</description>
          <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
          <units>Number of cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="7.71"/>
                    <measurement group_id="O2" value="7.3" spread="6.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cigarettes Smoked Per Day at Week 20</title>
        <description>Number of Cigarettes Smoked Per Day</description>
        <time_frame>Week 20</time_frame>
        <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cigarettes Smoked Per Day at Week 20</title>
          <description>Number of Cigarettes Smoked Per Day</description>
          <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
          <units>Number of cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="7.50"/>
                    <measurement group_id="O2" value="7.2" spread="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cigarettes Smoked Per Day at Week 26</title>
        <description>Number of Cigarettes Smoked Per Day</description>
        <time_frame>Week 26</time_frame>
        <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cigarettes Smoked Per Day at Week 26</title>
          <description>Number of Cigarettes Smoked Per Day</description>
          <population>Analysis was based on randomized participants who reported non-abstinence from smoking during the preceding week.</population>
          <units>Number of cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="6.06"/>
                    <measurement group_id="O2" value="7.5" spread="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Overall Product Rating at Week 1</title>
        <description>Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent).</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Overall Product Rating at Week 1</title>
          <description>Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="554"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 (Very Poor)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 (Excellent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Overall Product Rating at Week 6</title>
        <description>Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent).</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Overall Product Rating at Week 6</title>
          <description>Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 (Very Poor)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                    <measurement group_id="O2" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7"/>
                    <measurement group_id="O2" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3"/>
                    <measurement group_id="O2" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 (Excellent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Overall Product Rating at Week 12</title>
        <description>Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent).</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Overall Product Rating at Week 12</title>
          <description>Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 (Very Poor)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4"/>
                    <measurement group_id="O2" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 (Excellent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2"/>
                    <measurement group_id="O2" value="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke at Week 1</title>
        <description>Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective).</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke at Week 1</title>
          <description>Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="554"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all effective (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat effective (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately effective (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very effective (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                    <measurement group_id="O2" value="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely effective (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke at Week 6</title>
        <description>Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective).</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke at Week 6</title>
          <description>Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all effective (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat effective (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8"/>
                    <measurement group_id="O2" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately effective (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7"/>
                    <measurement group_id="O2" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very effective (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely effective (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke at Week 12</title>
        <description>Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective).</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke at Week 12</title>
          <description>Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all effective (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7"/>
                    <measurement group_id="O2" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat effective (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately effective (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1"/>
                    <measurement group_id="O2" value="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very effective (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                    <measurement group_id="O2" value="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely effective (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Speed of Action of the Product at Week 1</title>
        <description>Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast).</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Speed of Action of the Product at Week 1</title>
          <description>Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="554"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely slow (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very slow (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately slow (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly slow (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither fast nor slow (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sightly fast (6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately fast (7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very fast (8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely fast (9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Speed of Action of the Product at Week 6</title>
        <description>Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast).</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Speed of Action of the Product at Week 6</title>
          <description>Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely slow (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very slow (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately slow (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly slow (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither fast nor slow (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sightly fast (6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately fast (7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very fast (8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely fast (9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Speed of Action of the Product at Week 12</title>
        <description>Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast).</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Speed of Action of the Product at Week 12</title>
          <description>Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely slow (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very slow (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately slow (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly slow (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither fast nor slow (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                    <measurement group_id="O2" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sightly fast (6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                    <measurement group_id="O2" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately fast (7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very fast (8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely fast (9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Change of Opinion at Week 1 Concerning Product Compared to When First Used Product</title>
        <description>Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now).</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Change of Opinion at Week 1 Concerning Product Compared to When First Used Product</title>
          <description>Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="554"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>I like it much less now (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like it slightly less now (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like it about the same (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9"/>
                    <measurement group_id="O2" value="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like it slightly more now (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4"/>
                    <measurement group_id="O2" value="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like it much more now (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Change of Opinion at Week 6 Concerning Product Compared to When First Used Product</title>
        <description>Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now).</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Change of Opinion at Week 6 Concerning Product Compared to When First Used Product</title>
          <description>Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>I like it much less now (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like it slightly less now (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like it about the same (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9"/>
                    <measurement group_id="O2" value="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like it slightly more now (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3"/>
                    <measurement group_id="O2" value="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like it much more now (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Change of Opinion at Week 12 Concerning Product Compared to When First Used Product</title>
        <description>Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now).</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Change of Opinion at Week 12 Concerning Product Compared to When First Used Product</title>
          <description>Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>I like it much less now (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like it slightly less now (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like it about the same (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0"/>
                    <measurement group_id="O2" value="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like it slightly more now (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7"/>
                    <measurement group_id="O2" value="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like it much more now (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Product Convenience at Week 1</title>
        <description>Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient).</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Product Convenience at Week 1</title>
          <description>Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="554"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all convenient (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat convenient (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately convenient (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                    <measurement group_id="O2" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very convenient (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely convenient (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6"/>
                    <measurement group_id="O2" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Product Convenience at Week 6</title>
        <description>Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient).</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Product Convenience at Week 6</title>
          <description>Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all convenient (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat convenient (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately convenient (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very convenient (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely convenient (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6"/>
                    <measurement group_id="O2" value="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Distribution of the Participant Score for Product Convenience at Week 12</title>
        <description>Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient).</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Distribution of the Participant Score for Product Convenience at Week 12</title>
          <description>Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient).</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all convenient (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat convenient (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately convenient (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very convenient (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                    <measurement group_id="O2" value="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely convenient (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6"/>
                    <measurement group_id="O2" value="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure at Week 1</title>
        <description>Systolic blood pressure (mm Hg)</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at Week 1</title>
          <description>Systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.7" spread="15.54"/>
                    <measurement group_id="O2" value="124.7" spread="15.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure at Week 2</title>
        <description>Systolic blood pressure (mm Hg)</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at Week 2</title>
          <description>Systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.3" spread="15.42"/>
                    <measurement group_id="O2" value="123.7" spread="15.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure at Week 4</title>
        <description>Systolic blood pressure (mm Hg)</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at Week 4</title>
          <description>Systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.5" spread="15.29"/>
                    <measurement group_id="O2" value="122.9" spread="15.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure at Week 6</title>
        <description>Systolic blood pressure (mm Hg)</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at Week 6</title>
          <description>Systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.3" spread="14.05"/>
                    <measurement group_id="O2" value="122.4" spread="15.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure at Week 8</title>
        <description>Systolic blood pressure (mm Hg)</description>
        <time_frame>Week 8</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at Week 8</title>
          <description>Systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="457"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.0" spread="14.52"/>
                    <measurement group_id="O2" value="122.7" spread="14.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure at Week 12</title>
        <description>Systolic blood pressure (mm Hg)</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at Week 12</title>
          <description>Systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="434"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.8" spread="15.02"/>
                    <measurement group_id="O2" value="122.7" spread="15.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure at Week 16</title>
        <description>Systolic blood pressure (mm Hg)</description>
        <time_frame>Week 16</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at Week 16</title>
          <description>Systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.3" spread="14.94"/>
                    <measurement group_id="O2" value="122.8" spread="15.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure at Week 20</title>
        <description>Systolic blood pressure (mm Hg)</description>
        <time_frame>Week 20</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at Week 20</title>
          <description>Systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.4" spread="15.40"/>
                    <measurement group_id="O2" value="123.2" spread="15.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure at Week 26</title>
        <description>Systolic blood pressure (mm Hg)</description>
        <time_frame>Week 26</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at Week 26</title>
          <description>Systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="354"/>
                <count group_id="O2" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.2" spread="14.44"/>
                    <measurement group_id="O2" value="124.8" spread="15.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Week 1</title>
        <description>Change from baseline in systolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 1</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Week 1</title>
          <description>Change from baseline in systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="13.49"/>
                    <measurement group_id="O2" value="0.2" spread="13.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Week 2</title>
        <description>Change from baseline in systolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 2</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Week 2</title>
          <description>Change from baseline in systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="14.06"/>
                    <measurement group_id="O2" value="-0.7" spread="13.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Week 4</title>
        <description>Change from baseline in systolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Week 4</title>
          <description>Change from baseline in systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="14.59"/>
                    <measurement group_id="O2" value="-1.9" spread="14.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Week 6</title>
        <description>Change from baseline in systolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Week 6</title>
          <description>Change from baseline in systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="14.80"/>
                    <measurement group_id="O2" value="-2.2" spread="13.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Week 8</title>
        <description>Change from baseline in systolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Week 8</title>
          <description>Change from baseline in systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="457"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="15.26"/>
                    <measurement group_id="O2" value="-2.2" spread="14.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Week 12</title>
        <description>Change from baseline in systolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Week 12</title>
          <description>Change from baseline in systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="434"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="15.75"/>
                    <measurement group_id="O2" value="-2.4" spread="15.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Week 16</title>
        <description>Change from baseline in systolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Week 16</title>
          <description>Change from baseline in systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="14.95"/>
                    <measurement group_id="O2" value="-2.8" spread="15.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Week 20</title>
        <description>Change from baseline in systolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 20</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Week 20</title>
          <description>Change from baseline in systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="15.15"/>
                    <measurement group_id="O2" value="-2.0" spread="16.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Week 26</title>
        <description>Change from baseline in systolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 26</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Week 26</title>
          <description>Change from baseline in systolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="354"/>
                <count group_id="O2" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="14.61"/>
                    <measurement group_id="O2" value="-0.6" spread="15.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure at Week 1</title>
        <description>Diastolic blood pressure (mm Hg)</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure at Week 1</title>
          <description>Diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" spread="9.54"/>
                    <measurement group_id="O2" value="78.0" spread="9.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure at Week 2</title>
        <description>Diastolic blood pressure (mm Hg)</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure at Week 2</title>
          <description>Diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" spread="9.72"/>
                    <measurement group_id="O2" value="78.0" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure at Week 4</title>
        <description>Diastolic blood pressure (mm Hg)</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure at Week 4</title>
          <description>Diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" spread="9.58"/>
                    <measurement group_id="O2" value="77.6" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure at Week 6</title>
        <description>Diastolic blood pressure (mm Hg)</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure at Week 6</title>
          <description>Diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6" spread="9.86"/>
                    <measurement group_id="O2" value="76.5" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure at Week 8</title>
        <description>Diastolic blood pressure (mm Hg)</description>
        <time_frame>Week 8</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure at Week 8</title>
          <description>Diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="457"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" spread="9.82"/>
                    <measurement group_id="O2" value="77.3" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure at Week 12</title>
        <description>Diastolic blood pressure (mm Hg)</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure at Week 12</title>
          <description>Diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="434"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6" spread="10.12"/>
                    <measurement group_id="O2" value="77.4" spread="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure at Week 16</title>
        <description>Diastolic blood pressure (mm Hg)</description>
        <time_frame>Week 16</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure at Week 16</title>
          <description>Diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" spread="9.43"/>
                    <measurement group_id="O2" value="77.0" spread="10.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure at Week 20</title>
        <description>Diastolic blood pressure (mm Hg)</description>
        <time_frame>Week 20</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure at Week 20</title>
          <description>Diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" spread="9.91"/>
                    <measurement group_id="O2" value="76.8" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure at Week 26</title>
        <description>Diastolic blood pressure (mm Hg)</description>
        <time_frame>Week 26</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure at Week 26</title>
          <description>Diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="354"/>
                <count group_id="O2" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" spread="9.21"/>
                    <measurement group_id="O2" value="78.1" spread="10.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Week 1</title>
        <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 1</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Week 1</title>
          <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="8.98"/>
                    <measurement group_id="O2" value="0.5" spread="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Week 2</title>
        <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 2</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Week 2</title>
          <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="9.05"/>
                    <measurement group_id="O2" value="0.4" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Week 4</title>
        <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Week 4</title>
          <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="9.58"/>
                    <measurement group_id="O2" value="-0.1" spread="9.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Week 6</title>
        <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Week 6</title>
          <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="9.87"/>
                    <measurement group_id="O2" value="-1.0" spread="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Week 8</title>
        <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Week 8</title>
          <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="457"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="10.10"/>
                    <measurement group_id="O2" value="-0.1" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Week 12</title>
        <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Week 12</title>
          <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="434"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="10.06"/>
                    <measurement group_id="O2" value="-0.4" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Week 16</title>
        <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Week 16</title>
          <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="10.19"/>
                    <measurement group_id="O2" value="-0.8" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Week 20</title>
        <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 20</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Week 20</title>
          <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="10.07"/>
                    <measurement group_id="O2" value="-0.5" spread="10.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Week 26</title>
        <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
        <time_frame>Baseline to Week 26</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Week 26</title>
          <description>Change from baseline in diastolic blood pressure (mm Hg)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="354"/>
                <count group_id="O2" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="10.13"/>
                    <measurement group_id="O2" value="0.7" spread="10.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse at Week 1</title>
        <description>Pulse (beats per minute)</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse at Week 1</title>
          <description>Pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" spread="11.92"/>
                    <measurement group_id="O2" value="76.8" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse at Week 2</title>
        <description>Pulse (beats per minute)</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse at Week 2</title>
          <description>Pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9" spread="11.82"/>
                    <measurement group_id="O2" value="76.5" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse at Week 4</title>
        <description>Pulse (beats per minute)</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse at Week 4</title>
          <description>Pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6" spread="11.77"/>
                    <measurement group_id="O2" value="77.0" spread="11.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse at Week 6</title>
        <description>Pulse (beats per minute)</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse at Week 6</title>
          <description>Pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="11.41"/>
                    <measurement group_id="O2" value="75.2" spread="11.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse at Week 8</title>
        <description>Pulse (beats per minute)</description>
        <time_frame>Week 8</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse at Week 8</title>
          <description>Pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="456"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" spread="11.69"/>
                    <measurement group_id="O2" value="77.3" spread="11.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse at Week 12</title>
        <description>Pulse (beats per minute)</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse at Week 12</title>
          <description>Pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="434"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="11.46"/>
                    <measurement group_id="O2" value="76.1" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse at Week 16</title>
        <description>Pulse (beats per minute)</description>
        <time_frame>Week 16</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse at Week 16</title>
          <description>Pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" spread="11.94"/>
                    <measurement group_id="O2" value="76.2" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse at Week 20</title>
        <description>Pulse (beats per minute)</description>
        <time_frame>Week 20</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse at Week 20</title>
          <description>Pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" spread="11.70"/>
                    <measurement group_id="O2" value="76.2" spread="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse at Week 26</title>
        <description>Pulse (beats per minute)</description>
        <time_frame>Week 26</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse at Week 26</title>
          <description>Pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="354"/>
                <count group_id="O2" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" spread="11.98"/>
                    <measurement group_id="O2" value="76.0" spread="10.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse at Week 1</title>
        <description>Change from baseline in pulse (beats per minute)</description>
        <time_frame>Baseline to Week 1</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse at Week 1</title>
          <description>Change from baseline in pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="10.69"/>
                    <measurement group_id="O2" value="2.0" spread="10.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse at Week 2</title>
        <description>Change from baseline in pulse (beats per minute)</description>
        <time_frame>Baseline to Week 2</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse at Week 2</title>
          <description>Change from baseline in pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="10.75"/>
                    <measurement group_id="O2" value="1.8" spread="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse at Week 4</title>
        <description>Change from baseline in pulse (beats per minute)</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse at Week 4</title>
          <description>Change from baseline in pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="11.42"/>
                    <measurement group_id="O2" value="2.4" spread="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse at Week 6</title>
        <description>Change from baseline in pulse (beats per minute)</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse at Week 6</title>
          <description>Change from baseline in pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="11.23"/>
                    <measurement group_id="O2" value="0.7" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse at Week 8</title>
        <description>Change from baseline in pulse (beats per minute)</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse at Week 8</title>
          <description>Change from baseline in pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="456"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="11.51"/>
                    <measurement group_id="O2" value="2.7" spread="11.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse at Week 12</title>
        <description>Change from baseline in pulse (beats per minute)</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse at Week 12</title>
          <description>Change from baseline in pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="434"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="11.09"/>
                    <measurement group_id="O2" value="1.8" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse at Week 16</title>
        <description>Change from baseline in pulse (beats per minute)</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse at Week 16</title>
          <description>Change from baseline in pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="11.58"/>
                    <measurement group_id="O2" value="1.9" spread="11.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse at Week 20</title>
        <description>Change from baseline in pulse (beats per minute)</description>
        <time_frame>Baseline to Week 20</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse at Week 20</title>
          <description>Change from baseline in pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="11.25"/>
                    <measurement group_id="O2" value="2.0" spread="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse at Week 26</title>
        <description>Change from baseline in pulse (beats per minute)</description>
        <time_frame>Baseline to Week 26</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse at Week 26</title>
          <description>Change from baseline in pulse (beats per minute)</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="354"/>
                <count group_id="O2" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="11.16"/>
                    <measurement group_id="O2" value="1.8" spread="11.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New or Worsened Conditions in Lips/Labial Mucosa at Week 6 or When Withdrawn From Study</title>
        <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
        <time_frame>Week 6 or when withdrawn from study</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New or Worsened Conditions in Lips/Labial Mucosa at Week 6 or When Withdrawn From Study</title>
          <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New or Worsened Conditions in Buccal Mucosa at Week 6 or When Withdrawn From Study</title>
        <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
        <time_frame>Week 6 or when withdrawn from study</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New or Worsened Conditions in Buccal Mucosa at Week 6 or When Withdrawn From Study</title>
          <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New or Worsened Conditions in Mucobuccal Fold at Week 6 or When Withdrawn From Study</title>
        <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
        <time_frame>Week 6 or when withdrawn from study</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New or Worsened Conditions in Mucobuccal Fold at Week 6 or When Withdrawn From Study</title>
          <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New or Worsened Conditions in Sublingual Mucosa at Week 6 or When Withdrawn From Study</title>
        <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
        <time_frame>Week 6 or when withdrawn from study</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New or Worsened Conditions in Sublingual Mucosa at Week 6 or When Withdrawn From Study</title>
          <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New or Worsened Conditions in Gingiva at Week 6 or When Withdrawn From Study</title>
        <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
        <time_frame>Week 6 or when withdrawn from study</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New or Worsened Conditions in Gingiva at Week 6 or When Withdrawn From Study</title>
          <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New or Worsened Conditions in Tongue at Week 6 or When Withdrawn From Study</title>
        <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
        <time_frame>Week 6 or when withdrawn from study</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New or Worsened Conditions in Tongue at Week 6 or When Withdrawn From Study</title>
          <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New or Worsened Conditions in Hard/Soft Palate at Week 6 or When Withdrawn From Study</title>
        <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
        <time_frame>Week 6 or when withdrawn from study</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New or Worsened Conditions in Hard/Soft Palate at Week 6 or When Withdrawn From Study</title>
          <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New or Worsened Conditions in Uvula/Oropharynx at Week 6 or When Withdrawn From Study</title>
        <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
        <time_frame>Week 6 or when withdrawn from study</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New or Worsened Conditions in Uvula/Oropharynx at Week 6 or When Withdrawn From Study</title>
          <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New or Worsened Conditions in Visual Mouth Inspection Overall at Week 6 or When Withdrawn From Study</title>
        <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
        <time_frame>Week 6 or when withdrawn from study</time_frame>
        <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New or Worsened Conditions in Visual Mouth Inspection Overall at Week 6 or When Withdrawn From Study</title>
          <description>Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.</description>
          <population>Analysis was based on the Safety Analysis Set which included all randomized participants who received study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 6</title>
        <description>Change from baseline in body weight</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 6</title>
          <description>Change from baseline in body weight</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="471"/>
                <count group_id="O2" value="472"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="5.73"/>
                    <measurement group_id="O2" value="0.7" spread="6.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 12</title>
        <description>Change from baseline in body weight</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 12</title>
          <description>Change from baseline in body weight</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="7.40"/>
                    <measurement group_id="O2" value="0.4" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 26</title>
        <description>Change from baseline in body weight</description>
        <time_frame>Baseline to Week 26</time_frame>
        <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 26</title>
          <description>Change from baseline in body weight</description>
          <population>Analysis was based on the Full Analysis Set which included all randomized participants.</population>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="11.07"/>
                    <measurement group_id="O2" value="1.0" spread="8.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 6 in Participants Verified Continuously Abstinent From Smoking From the Week 2 Visit</title>
        <description>Change from baseline in body weight</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>Analysis was based on randomized participants verified continuously abstinent from smoking since the Week 2 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 6 in Participants Verified Continuously Abstinent From Smoking From the Week 2 Visit</title>
          <description>Change from baseline in body weight</description>
          <population>Analysis was based on randomized participants verified continuously abstinent from smoking since the Week 2 visit.</population>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="5.93"/>
                    <measurement group_id="O2" value="3.7" spread="5.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean change from baseline in body weight between treatments. The alternative hypothesis was a difference in mean change from baseline in body weight between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.558</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment, baseline smoking category, study site, and baseline weight were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.679</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.42</ci_lower_limit>
            <ci_upper_limit>4.41</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 12 in Participants Verified Continuously Abstinent From Smoking From the Week 2 Visit</title>
        <description>Change from baseline in body weight</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Analysis was based on randomized participants verified continuously abstinent from smoking since the Week 2 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 12 in Participants Verified Continuously Abstinent From Smoking From the Week 2 Visit</title>
          <description>Change from baseline in body weight</description>
          <population>Analysis was based on randomized participants verified continuously abstinent from smoking since the Week 2 visit.</population>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="8.89"/>
                    <measurement group_id="O2" value="6.4" spread="6.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean change from baseline in body weight between treatments. The alternative hypothesis was a difference in mean change from baseline in body weight between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.383</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment, baseline smoking category, study site, and baseline weight were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.409</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.03</ci_lower_limit>
            <ci_upper_limit>10.11</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 26 in Participants Verified Continuously Abstinent From Smoking From the Week 2 Visit</title>
        <description>Change from baseline in body weight</description>
        <time_frame>Baseline to Week 26</time_frame>
        <population>Analysis was based on randomized participants verified continuously abstinent from smoking since the Week 2 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 26 in Participants Verified Continuously Abstinent From Smoking From the Week 2 Visit</title>
          <description>Change from baseline in body weight</description>
          <population>Analysis was based on randomized participants verified continuously abstinent from smoking since the Week 2 visit.</population>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="5.67"/>
                    <measurement group_id="O2" value="9.3" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean change from baseline in body weight between treatments. The alternative hypothesis was a difference in mean change from baseline in body weight between treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.138</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment, baseline smoking category, study site, and baseline weight were factors.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>7.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.573</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.56</ci_lower_limit>
            <ci_upper_limit>16.83</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Nicotine - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 26-week end-of-study visit or through early termination visit; + up to 30 days for unresolved adverse events; +30 days for serious adverse events</time_frame>
      <desc>AEs were systematically collected during the study. AEs that were unresolved upon completion or termination from the study were followed for up to 30 calendar days until the event or its sequelae resolved or stabilized. Serious AEs were collected through 30 calendar days after the participants last study visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo capsaicin mouth spray, 0 mg nicotine/dose, intraorally per label directions</description>
        </group>
        <group group_id="E2">
          <title>Nicotine</title>
          <description>Nicotine mouth spray, 1 mg nicotine/dose, intraorally per label directions</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Secondary Adrenocortical Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness Unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Retinal Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Post Procedural Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Postoperative Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Sternal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Toxicity to Various Agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Plasma Cell Myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Substance Abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Renal Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="349" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="252" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submission for publication, PI was to provide sponsor with  60 days for publication review. No publication that included sponsor confidential information was to be submitted without sponsors consent. If requested, the PI was to withhold publication for up to 60 additional days to allow for patent application filing. First publication of study results was to be a joint, multicenter publication; if not submitted within 6 months after end of study, the PI may publish the site results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Myers, MD, Director, Clinical Research</name_or_title>
      <organization>JNJWorldwide</organization>
      <phone>(215) 273-8421 USA EST</phone>
      <email>AMyers3@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

